Background: Pancreatic carcinoma remains a treatment-refractory cancer with a
INTRODUCTION
Pancreatic cancer is the fourth leading cause of cancer death in both men and women. Currently, most pancreatic-cancer patients die within a year of diagnosis.
When the tumor becomes symptomatic, 60 to 80% of the patients already have locally advanced or metastatic disease allowing essentially palliative therapy, with a 5-year survival rate of less than 5%. 1 Recent evaluation of gemcitabine based combination chemotherapy trials in advanced pancreatic cancer have demonstrated significant, but low response rates and disappointing effects on survival. 2 The strategies of earlier attack on cancer by perioperative adjuvant or neoadjuvant therapy were expected to be more promising.
However, the recently reported retrospective and prospective analyses of adjuvant chemo-radiotherapy of pancreas carcinoma, 3 as well as the results of preoperative chemo-radiation therapies, 4 have again demonstrated significant, but very modest therapeutic gains. Similarly, the results from a recent phase III trial, evaluating the advantage of the association of erlotinib with gemcitabine, showed a significant, but low improvement, as compared to gemcitabine alone treatment, with a median survival of 6.24 vs 5.91 months, as well as a one year survival of 23% vs 17%, respectively. 5 In the field of mAb therapies and following the demonstration of the expression of both EGFR and HER2 in pancreatic carcinomas 6, 7 and the known implication of those receptors in the malignant phenotype, [8] [9] [10] [11] we have recently demonstrated that the coinjection of anti-EGFR and anti-HER2 mAbs had a significant synergic effect in the treatment of human pancreatic carcinoma xenografts, as compared to the effect of each mAb alone. 12 Our results were recently confirmed and extended by the demonstration that different pairs of anti-HER2 mAbs had a synergistic anti-tumor effect. 13 Here, we are evaluating, if the combined anti-EGFR/anti-HER2 mAbs (2 mAbs) targeted therapy can result in better efficacy than the current standard chemotherapy, gemcitabine, in a first and second line therapy.
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METHODS

Monoclonal antibodies and drugs
Cetuximab was purchased from Merck KGaA (Darmstadt, Germany),
Trastuzumab from Roche Pharma AG (Grenzach-Wyhlen, Germany) and
Gemcitabine from Lilly France (Pages, France). F(ab)' 2 fragments of cetuximab and trastuzumab were prepared by pepsine digestion followed by filtration on a Superdex 200 column. Absence of intact mAb contamination was checked by lack of any cytotoxicity induction by NK cells on antigen positive target cells.
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Cell lines
BxPC-3 and MiaPaCa-2 pancreatic cell lines were from ATCC (Rockville, MD, USA). The Capan-1 was kindly provided by Pr L. Buscail (Toulouse, France).
Xenograft study and treatment procedure
All in vivo experiments were performed in compliance with the national regulations and ethical guidelines for experimental animal studies in an accredited establishment (Agreement No. B34-172-27). Six week-old female athymic mice, (Harlan, Le Malcourlet, France), were xenografted subcutaneously (s.c.) with BxPC-3 (3.5 X 10 6 ), MiaPaCa-2 (5 X 10 6 ), and Capan-1 (10 X 10 6 ) cells. Tumor-bearing mice were randomized when tumors reached a miminum of 50 mm 3 and sacrificed when tumor reached a volume larger than 1000 mm 3 .
In first line, mice were treated twice a week either by intraperitoneal injections (i.p.) of combined trastuzumab/cetuximab (ratio 1:1; 2 mg/kg of each mAb) or gemcitabine (150 mg/kg) diluted in 0.15 ml saline.
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In second line, 20 mice were treated twice a week with gemcitabine alone (150 mg/kg). For 10 mice presenting a tumour progression (volume increase at least twofold from initial measurement) the gemcitabine treatment was replaced by the combined trastuzumab/cetuximab i.p. injections twice a week (ratio 1:1; 2 mg/kg).
Others 10 mice were continuously treated by gemcitabine.
To determine the implication of the Fc portion of antibodies, BxPC-3 xenografted mice were treated twice a week for four weeks with F(ab') 2 fragments from both trastuzumab and cetuximab (ratio 1:1; 1.35 mg/kg of each fragment) or cetuximab F(ab') 2 alone, at the same dose, or intact trastuzumab and cetuximab (ratio 1:1;
2mg/kg). The concentration of fragments was adjusted to be at the same molarity 
K-Ras mutation analysis
High-molecular-weight DNA was extracted using a Qiamp DNA mini kit (Qiagen, Courtaboeuf, France). Direct sequencing of the K-Ras gene codon 12 and 13 was done with a 3130 Genetic Analyzer (Applied Biosystems, Courtaboeuf, France), using the Bigdye terminators v1.1 cycle sequencing kit (Applied Biosystems).
Immunohistochemical analyses
Seven days post treatment, tumors were harvested and fixed 12h in buffered formalin, and embedded in paraffin. 
Western blot analysis
Seven days post treatment, tumors were harvested and lysed as described 12 .
After electrophoresis, the proteins were transferred to a polyvinylidene difluoride membranes (Millipore Co., Bedford, MA) which were saturated in PBS implantation and to different groups. Interaction terms were built into the model.
Random intercept and random slope were included to take into account time effect.
The coefficients of the model were estimated by maximum likelihood and considered significant at the 0.05 level.
Survival rates were estimated from the date of the xenograft until the date when the tumor reach a volume of 1000 mm 3 using the Kaplan-Meier method.
Median survival was presented with 95% confidence intervals. Survival curves were compared using the Log-rank test. Statistical analysis was performed using STATA 10.0 software. 
RESULTS
Pancreatic cell lines characteristics
Immunohistochemical analyses of the three human pancreatic carcinoma xenografted in nude mice showed a very low HER2 expression, but a high level of EGFR, classified as +++ for both BxPC-3 and Capan-1 and as ++ for MiaPaCa-2 (table 1) . When tested by flow cytometry, 15 the three pancreatic carcinoma cell lines showed a moderate expression of HER2 (table 1) .
The presence of G12C mutation was confirmed in the MiaPaCa-2 and Capan-1 carcinoma cell line, while it was not observed in BxPC-3 line (table 1) .
16,17
First line combined antibody therapy vs gemcitabine
Gemcitabine dose was fixed at 150 mg/kg/injection and antibody doses were selected on the basis of our previous experiments.
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In the three human pancreatic carcinoma xenografts, the survival of mice treated with 
Immunohistochemistry (IHC) and Western Blot analysis
To assess the in vivo mechanisms underlying the anti-tumor activity of the two mAbs combination, we analyzed in BxPC-3 tumor xenografts, by IHC, the EGFR expression, the EGFR phosphorylation level, and the proliferative Ki67 index, after one week of 2mAbs or gemcitabine treatment. As shown in figure 3 , the 2mAbs treatment induced a marked decrease of the EGFR expression, EGFR phosphorylation and Ki67 index compared to untreated controls and gemcitabine treatment. The AKT phosphorylation after the same two treatments was assessed by
Western Blot analysis, which showed almost complete inhibition of P-AKT after 2mAbs treatment and only minor inhibition after gemcitabine compared to untreated tumor control.
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Comparison of F(ab') 2 fragments from the 2 mAbs with intact antibodies
In order to separately analyze the in vivo direct effect of the mAbs binding sites on the EGF and HER2 receptors, as compared with the Fc-dependant effector functions of the antibodies, F(ab') 2 fragments from both cetuximab and trastuzumab were prepared and their therapeutic properties evaluated. As shown in figure 4 , the F(ab') 2 fragments from the two mAbs had a significant anti-tumor effect compared with untreated controls (p<0.001), as well as with F(ab') 2 from anti-EGFR mAb alone, which had no anti-tumor effect (p=0.510). As expected, injection of the two intact mAbs had a more pronounced anti-tumor effect compared to the two fragments (p=0.002). Of particular interest was the positive impact of this treatment despite the low HER2 expression by all three target carcinomas and despite the presence of a K-ras mutation on two of them. It was recently shown that the efficacy of cetuximab in metastastic colorectal carcinoma was almost abolished in K-ras mutated tumors. 18 In pancreatic cancer, where K-ras mutations are the norm (90%), trials evaluating cetuximab plus gemcitabine-cisplatin vs gemcitabine-cisplatine did not increase response or survival of patients. 19 Here, a clear therapeutic benefit of cetuximab and trastuzumab combination was observed in two K-ras mutated pancreatic carcinomas, suggesting that the lack of clinical benefit of anti-EGFR mAb could be by-passed by combining this mAb with the anti-HER2 mAb.
All three tested pancreatic carcinoma lines responded better to 2mAbs whatever their respective sensitivity to gemcitabine. In case of high sensitivity to chemotherapy (BxPC-3), i.e. in the best condition of gemcitabine efficacy, 2mAbs
significantly increased tumor responses and cured 3/9 mice, while no cure was obtained with gemcitabine.
The mechanism of action of the synergism of the two anti-EGFR and HER2 mAbs is not yet entirely understood, as is the case for several approved mAbs whose mode of action is not entirely unraveled. It was shown that an anti-EGFR mAb could increase the in vitro growth inhibition of an anti-HER2 mAb 9 or that two anti-EGFR and HER2 mAbs had a synergistic effect in the down regulation of the receptor tyrosine-kinases activity 10 . However, our in vivo results were the first to demonstrate unequivocally that the two anti-EGFR and HER2 mAbs can act synergistically in the treatment of human carcinoma xenografts. 12 Thus, we concentrated our effort on some in vivo experiments that could shed some light on the mechanism of action of 2mAbs.
First, we showed that the 2mAbs induced a decrease of the proliferation index 
